Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585616 | 0.93 | KDM4E (0.47) | HTR7ALDH1A1KDM4ESMN1; SMN2SLC6A2 | |
| SCHEMBL5586046 | 0.91 | KDM4E (0.52) | HTR7ALDH1A1KDM4ESMN1; SMN2SLC6A2 | |
| SCHEMBL5585671 | 0.86 | SLC6A2 (0.46) | HTR7ALDH1A1KDM4ESMN1; SMN2SLC6A2 | |
| SCHEMBL5585853 | 0.84 | CHRNB2 (0.49) | HTR7SLC6A2CHRNB2CHRNA4 | |
| SCHEMBL5585586 | 0.82 | HTR7 (0.69) | HTR7ALDH1A1KDM4ESMN1; SMN2HTR1B | |
| SCHEMBL236730 | 0.81 | SLC6A2 (0.47) | ALDH1A1KDM4ESMN1; SMN2SLC6A2 | |
| SCHEMBL5585628 | 0.79 | LTA4H (0.51) | HTR7HTR1BCHRNB2CHRNA4DRD2 | |
| SCHEMBL5585335 | 0.79 | SLC6A2 (0.42) | HTR7ALDH1A1KDM4ESMN1; SMN2SLC6A2 | |
| SCHEMBL4318642 | 0.79 | CHRNB4 (0.48) | ALDH1A1SMN1; SMN2SLC6A2 | |
| SCHEMBL5585621 | 0.79 | SLC6A2 (0.62) | ALDH1A1KDM4ESLC6A2HTR1BCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329826-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | PROXIMAGEN LIMITED (GB) | 2014-11-06 | — | — | US | disclosed |
| US-8835439-B2 | Pharmaceutical composition containing (2R)-methyl-1-3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinylpiperazine L-malate for treatment of serotonin-related diseases | PROXIMAGEN LIMITED (GB) | 2014-09-16 | — | — | US | disclosed |
| US-20130158266-A1 | (2R)-1-(3-Chloro-2-Pyrazinyl)-2-Methylpiperazine And Salts Thereof | BIOVITRUM AB (PUBL) (SE) | 2013-06-20 | — | — | US | disclosed |
| US-8410113-B2 | (2R)-1-(3-chloro-2-pyrazinyl)-2-methylpiperazine and salts thereof | BIOVITRUM AB (PUBL) (SE) | 2013-04-02 | — | — | US | disclosed |
| US-20120010410-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | BIOVITRUM AB, A SWEDEN CORPORATION | 2012-01-12 | — | — | US | disclosed |
| US-20120004241-A1 | SUCCINATE SALT OF (2R)-METHYL-1-PIPERAZINE | BIOVITRUM AB, A SWEDEN CORPORATION | 2012-01-05 | — | — | US | disclosed |
| US-8030316-B2 | Malate salt of (2R)-methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine | BIOVITRUM AB (PUBL) (SE) | 2011-10-04 | — | — | US | disclosed |
| US-7820677-B2 | Phosphoric acid addition salt of (2R)-1-[3-(2-{[2-(2-dimethylaminoethoxy)-3-pyridinyl]oxy}-ethoxy)-2-pyrazinyl]-2-methylpiperazine | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2010-10-26 | — | — | US | disclosed |
| US-20100256374-A1 | NOVEL PROCESS | BIOVITRUM AB, A SWEDEN CORPORATION | 2010-10-07 | — | — | US | disclosed |
| EP-1645558-B1 | Piperazinylpyrazines as serotonin 5-HT2C receptor modulators | BIOVITRUM AB PUBL (SE) | 2008-06-11 | — | — | EP | disclosed |
| US-7129354-B2 | Process for the preparation of stable acid addition salt of 2,3-disubstituted pyrazine compounds | BIOVITRUM AB (SE) | 2006-10-31 | — | — | US | disclosed |
| EP-1529043-B1 | Process for the preparation of 2-methyl piperazine derivatives. | BIOVITRUM AB (SE) | 2006-08-02 | — | — | EP | disclosed |
| US-20060142578-A1 | Novel process | BIOVITRUM AB, A SWEDEN CORPORATION | 2006-06-29 | — | — | US | disclosed |
| EP-1645558-A1 | Piperazinylpyrazines as serotonin 5-HT2C receptor modulators | BIOVITRUM AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1529043-A1 | NOVEL PROCESS | Biovitrum AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| EP-1513831-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040038981-A1 | Novel Process | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-26 | — | — | US | disclosed |
| US-20040029888-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-12 | — | — | US | disclosed |
| WO-2004000830-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| WO-2004000829-A1 | NOVEL PROCESS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004241-A1 | SUCCINATE SALT OF (2R)-METHYL-1-PIPERAZINE | SUCNR1, HTR5A, HTR2C | HTR7 37/4885ALDH1A1 160/4885KDM4E 2291/4885 |
| US-20100256374-A1 | NOVEL PROCESS | HTR1A, TPH1, HTR5A | HTR7 21/4885ALDH1A1 458/4885KDM4E 4012/4885 |
| US-20130158266-A1 | (2R)-1-(3-Chloro-2-Pyrazinyl)-2-Methylpiperazine And Salts Thereof | HTR2C, HTR5A, HTR2A | HTR7 15/4885ALDH1A1 286/4885KDM4E 3179/4885 |
| US-20040038981-A1 | Novel Process | HTR1A, TPH1, HTR1B | HTR7 18/4885ALDH1A1 193/4885KDM4E 3310/4885 |
| US-20060142578-A1 | Novel process | HTR1A, TPH1, HTR5A | HTR7 18/4885ALDH1A1 471/4885KDM4E 4340/4885 |
| US-20040029888-A1 | Novel compounds, their use and preparation | TPH1, TPH2, HTR1A | HTR7 15/4885ALDH1A1 445/4885KDM4E 3125/4885 |
| US-20120010410-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | HTR2C, HTR5A, HTR2A | HTR7 15/4885ALDH1A1 286/4885KDM4E 3179/4885 |
| US-20140329826-A1 | (2R)-1-(3-CHLORO-2-PYRAZINYL)-2-METHYLPIPERAZINE AND SALTS THEREOF | HTR2C, HTR5A, HTR2A | HTR7 15/4885ALDH1A1 286/4885KDM4E 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.